Treatment library
Loading treatment roster
Preparing current medications, procedures, devices, and historical context.
Treatment library
Preparing current medications, procedures, devices, and historical context.
Novo Nordisk’s semaglutide brand for type 2 diabetes. It appears in nearly every weight-loss conversation because patients frequently confuse it with Wegovy or compare access paths between the two.
FDA-approved for type 2 diabetes, not for chronic weight management. Its weight-loss relevance comes from shared molecule confusion with Wegovy.
GLP-1 receptor agonist
Often easier to cover through diabetes benefits than obesity-only coverage, but plans and diagnosis requirements vary.
GLP-1 receptor agonist
Novo Nordisk’s semaglutide brand for type 2 diabetes. It appears in nearly every weight-loss conversation because patients frequently confuse it with Wegovy or compare access paths between the two.
medication
current
2017
Ozempic
semaglutide
Novo Nordisk
No U.S. generic equivalent.
semaglutide
Branded medication with high cash-pay cost when not covered through diabetes benefits or other access programs.
Often easier to cover through diabetes benefits than obesity-only coverage, but plans and diagnosis requirements vary.
Most relevant for readers trying to understand the semaglutide molecule, diabetes versus obesity labeling, and coverage confusion.
Ozempic is approved for type 2 diabetes, not obesity. There is no BMI threshold in the label. Off-label prescribing for weight loss exists but is not the approved indication, and insurance coverage for off-label use is inconsistent.
The list price runs roughly $935 per month. Diabetes formulary coverage is generally stronger than obesity coverage, which makes Ozempic more accessible for patients who have a type 2 diabetes diagnosis. Manufacturer savings programs are available for eligible patients.
Ozempic is often the first semaglutide product patients encounter, because diabetes coverage is generally easier to obtain than obesity coverage. Patients who start Ozempic for type 2 diabetes frequently learn about the weight-loss effects and then ask about Wegovy. Confusion between the two brands is extremely common. The injection is once weekly using a multi-dose pen, and the dosing and pen format are different from Wegovy.
Ozempic is central to patient confusion in this market because it shares semaglutide with Wegovy while carrying a different label and dosing framework.
The SUSTAIN trials studied Ozempic for type 2 diabetes, not obesity. Key results: HbA1c reduction of 1.2-1.8% depending on dose and comparator. Weight loss of roughly 9 to 14 pounds was observed as a secondary outcome, not the primary endpoint. Ozempic was not studied in pivotal weight-loss trials; those belong to Wegovy.
Class warnings overlap with Wegovy because the active ingredient is the same semaglutide molecule.
nausea, vomiting, diarrhea, constipation, abdominal pain
The side effect profile mirrors Wegovy because the active molecule is the same semaglutide. Nausea, vomiting, diarrhea, and constipation are the most common adverse events. The maximum labeled Ozempic dose (2 mg) is lower than the Wegovy maintenance dose (2.4 mg), which may mean a slightly lower gastrointestinal burden at maintenance compared with the obesity formulation.
GLP-1 receptor agonist
Once-weekly subcutaneous injection with titration up to 2 mg for labeled diabetes use.
Prefilled multi-dose injection pen.
These are the official or reference sources used to anchor this treatment profile.
Treatment availability, dosing, cash pricing, and insurance coverage change often. Verify current details with your clinician, pharmacist, surgeon, device program, and insurer before starting, switching, or paying for treatment.